Industria farmacéutica, compra de conciencias y bioética

  • Daniel Simancas-Racines Universidad UTE Ecuador
  • Paula Zambrano-Achig Universidad UTE Ecuador
  • Camila Montesinos Universidad UTE Ecuador
Palabras clave: Bioética, atención primaria, salud, APS

Resumen

La cooperación entre la industria y la salud siempre ha estado presente con el objetivo de contribuir en las diferentes áreas médicas. Pero debido al interés de la industria en aumentar sus ganancias, se ha redefinido la relación con los médicos y se ha demostrado que el “Big Pharma” invierte en los profesionales para que ellos sean los comerciantes de sus productos.

Descargas

La descarga de datos todavía no está disponible.

Biografía del autor/a

Daniel Simancas-Racines, Universidad UTE Ecuador

Centro de Investigación en Salud Pública y Epidemiología Clínica (CISPEC). Facultad de Ciencias de la Salud "Eugenio Espejo". Universidad UTE. Quito, Ecuador
ID-Orcid: https://orcid.org/0000-0002-3641-1501

Paula Zambrano-Achig, Universidad UTE Ecuador

Centro de Investigación en Salud Pública y Epidemiología Clínica (CISPEC). Facultad de Ciencias de la Salud "Eugenio Espejo". Universidad UTE. Quito, Ecuador
ID-Orcid: https://orcid.org/0000-0003-3632-4296

Camila Montesinos, Universidad UTE Ecuador

Centro de Investigación en Salud Pública y Epidemiología Clínica (CISPEC). Facultad de Ciencias de la Salud "Eugenio Espejo". Universidad UTE. Quito, Ecuador

Citas

1. Organización Mundial de la Salud (OMS). Declaración de la OMS en relación con las denuncias de conflictos de intereses y la «falsa» pandemia [Internet]. 2010. Available from: https://www.who.int/mediacentre/news/statements/2010/h1n1_pandemic_20100122/es/
2. Novella S. Demonizing “Big Pharma” [Internet]. Science-Based Medicine. 2010. Available from: https://sciencebasedmedicine.org/demonizing-big-pharma/
3. Blaskiewicz R. The Big Pharma conspiracy theory. Med Writ. 2013;22(4):259–61.
4. DeAngelis CD. Big Pharma Profits and the Public Loses. Milbank Q. 2016;94(1):30–3.
5. Tiller L. Getting Their Fix: Doctor’s Dependency on Big Pharma. Bus. Entrep Tax L. 2018;2:492.
6. Moynihan R. Education and debate between doctors and drug companies . 1 : Entanglement. Bmj. 2003;326(May):1189–92.
7. De Lotbiniere-Bassett MP, McDonald PJ. Industry Financial Relationships in Neurosurgery in 2015: Analysis of the Sunshine Act Open Payments Database. World Neurosurg [Internet]. 2018;114:e920–5. Available from: https://doi.org/10.1016/j.wneu.2018.03.116
8. Robbins NM, Meyer MJ, Bernat JL. Scope and Nature of Financial Conflicts of Interest Between Neurologists and Industry: 2013-2016. Neurology [Internet]. 2019;93(10):438–49. Available from: https://pubmed.ncbi.nlm.nih.gov/31383793-scope-and-nature-of-financial-conflicts-of-interest-between-neurologists-and-industry-2013-2016/
9. Ahlawat A, Narayanaswami P. Financial relationships between neurologists and industry: The 2015 Open Payments database. Neurology. 2018;90(23):1063–70.
10. Bernat JL, Swash M. Relationships between neurologists and industry. Neurology. 2018;90(23):1047–8.
11. Orthopaedic A, Orthopaedic A, Task M, Relationships S. American Orthopaedic Association Orthopaedic Institute of Medicine Report from the Task Force on Surgeon-Industry Relationships in the Discipline of Orthopaedic Surgery. J Bone Joint Surg Am. 2012;89(1):10–2.
12. Iyer S, Derman P, Sandhu HS. Orthopaedics and the physician payments sunshine act an examination of payments to U.S. Orthopaedic surgeons in the open payments database. J Bone Jt Surg - Am Vol. 2016;98(5):e18.
13. Teplitsky S, Perez T, Leong JY, Xie K, Murphy A, Shenot PJ. Industry payments to female pelvic medicine and reconstructive surgeons: an analysis of Sunshine Act open payments from 2014–2017. Int Urogynecol J. 2019;
14. Muffly TM, Giamberardino WL, Guido J, Weterings R, Bastow B, Sheeder J. Industry payments to obstetricians and gynecologists under the sunshine act. Obstet Gynecol. 2018;132(1):9–17.
15. Chao AH, Gangopadhyay N. Industry financial relationships in plastic surgery: Analysis of the sunshine act open payments database. Plast Reconstr Surg. 2016;138(2):341e-348e.
16. Probst P, Grummich K, Ulrich A, Büchler MW, Knebel P, Diener MK. Association of industry sponsorship and positive outcome in randomised controlled trials in general and abdominal surgery: Protocol for a systematic review and empirical study. Syst Rev. 2014;3(1):1–6.
17. Luce EA. Financial conflicts of interest in plastic surgery: Background, potential for bias, disclosure, and transparency. Plast Reconstr Surg. 2015;135(4):1149–55.
18. Marshall DC, Moy B, Jackson ME, Mackey TK, Hattangadi-Gluth JA. Distribution and patterns of industry-related payments to oncologists in 2014. J Natl Cancer Inst. 2016;108(12):1–10.
19. Goupil B, Balusson F, Naudet F, Esvan M, Bastian B, Chapron A, et al. Association between gifts from pharmaceutical companies to French general practitioners and their drug prescribing patterns in 2016: Retrospective study using the French Transparency in Healthcare and National Health Data System databases. BMJ. 2019;367:1–9.
Publicado
2019-11-30
Cómo citar
1.
Simancas-Racines D, Zambrano-Achig P, Montesinos C. Industria farmacéutica, compra de conciencias y bioética. PFR [Internet]. 30 de noviembre de 2019 [citado 21 de junio de 2024];4(3). Disponible en: https://practicafamiliarrural.org/index.php/pfr/article/view/120